Abstract
Background Viral sequencing has made critical contributions to our understanding of and response to the COVID-19 pandemic, but sequencing capacity and bioinformatic expertise remain limited in many settings. This proof-of-principle study aimed to demonstrate the utility of a cloud-based sequencing analysis pipeline, the Tiled Amplicon Pipeline (TAP), for rapid and collaborative SARS-CoV-2 sequencing across seven globally distributed sites.
Methods In this cross-sectional study from July to August 2022, seven sites submitted all SARS-CoV-2 sequence data generated over a two-week period to our cloud platform. No patient identifying information was uploaded, and human reads were removed prior to upload to the cloud. Users could opt in to share sample information with collaborators via a tagging system. The pipeline performed sequence assembly, lineage identification and relatedness analysis.
Results Seven sites contributed 5,432 sequences, of which 5,342 (98.3%) were from clinical samples and 90 (1.7%) were controls. Of the clinical samples that were correctly assembled, 3,439/4,179 (82.3%) had sufficient coverage for lineage assignment. Omicron lineages dominated, with BA.5, BA.4 and BA.2 comprising the vast majority, consistent with contemporary epidemiological observations at the time. Phylogenetic analysis demonstrated low diversity within lineages, and genotypically identical or highly similar sequences were recovered from globally disparate sites.
Conclusions A cloud-based analysis platform like TAP addresses bioinformatic bottlenecks and facilitates collaboration in pathogen surveillance, enhancing epidemic and pandemic preparedness.
Article Summary Line: A cross-sectional study of SARS-CoV-2 sequencing demonstrates that cloud-based sequencing analysis has the power to relieve bioinformatic bottlenecks, and facilitate collaboration in pathogen surveillance to enhance pandemic preparedness.
Competing Interest Statement
AvG and NW have received grant funding from Sanofi and The Bill and Melinda Gates Foundation. PWF receives consultancy fees from the Ellison Institute of Technology, Oxford. JT, DWC and TEAP receive funding from the Ellison Institute of Technology, Oxford.
Funding Statement
GPAS is a non-profit organisation, and GPAS cloud infrastructure was supported by a donation from Oracle Corporation. For this study, all GPAS services were offered free of charge to all sites, and staff costs for the analysis team were met by the University of Oxford, with support from the National institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). TAP is deployed on the EIT Pathogena platform, funded by the Ellison Institute of Technology Oxford. EIT Pathogena is free at the point of use for users in low- and middle-income countries. Sequencing activities for NICD are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (NU51IP000930); the South African Medical Research Council (SAMRC) with funds received from the South African Department of Science and Innovation; the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; Africa PGI, the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); and the Department of Health and Social Care's Fleming Fund using UK aid. NICD sequencing was also supported by The Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the Centers for Disease Control and Prevention (CDC) and the COVID International Task Force (ITF) funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021. Genomic surveillance conducted in Vietnam was supported by the Wellcome Trust (222574/Z/21/Z). L.V.T. is supported by the Wellcome Trust of Great Britain (204904/Z/16/Z and 226120/Z/22/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Services Ethics lead of University of Oxford waived the requirement for ethical review for this work. We can provide a letter from University of Oxford research sponsorship and ethics lead, confirming that this study did not require review according to UK Health Research Authority requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.